Zobrazeno 1 - 10
of 46
pro vyhledávání: '"Catherine Leyh"'
Autor:
Tom Luedde, Karel Kostev, Christoph Roderburg, Jennis Kandler, Alexander Mertens, Sven Heiko Loosen, Isabel Klein, Catherine Leyh, Sarah Krieg
Publikováno v:
BMJ Open Gastroenterology, Vol 11, Iss 1 (2024)
Background Helicobacter pylori (H. pylori) is a gram-negative gastrointestinal pathogen that colonises the human stomach and is considered a major risk factor for gastric cancer and mucosa-associated lymphoid tissue lymphoma. Furthermore, H. pylori i
Externí odkaz:
https://doaj.org/article/fa785caf714245de90b10effb8de5b4f
Autor:
Najib Ben Khaled, Marie Möller, Leonie S. Jochheim, Catherine Leyh, Ursula Ehmer, Katrin Böttcher, Matthias Pinter, Lorenz Balcar, Bernhard Scheiner, Alexander Weich, Hans Benno Leicht, Valentina Zarka, Liangtao Ye, Julia Schneider, Ignazio Piseddu, Osman Öcal, Monika Rau, Friedrich Sinner, Marino Venerito, Simon Johannes Gairing, Friedrich Förster, Julia Mayerle, Enrico N. De Toni, Andreas Geier, Florian P. Reiter
Publikováno v:
JHEP Reports, Vol 6, Iss 6, Pp 101065- (2024)
Background & Aims: Atezolizumab/bevacizumab (atezo/bev) and lenvatinib have demonstrated efficacy as first-line therapies for hepatocellular carcinoma (HCC). However, vascular endothelial growth factor (VEGF) inhibition with these therapies may be as
Externí odkaz:
https://doaj.org/article/8bfa5b4342fd47ce9b2a38f731714629
Autor:
Fabian Finkelmeier, Bernhard Scheiner, Catherine Leyh, Jan Best, Thorben Wilhelm Fründt, Carolin Czauderna, Alica Beutel, Dominik Bettinger, Johannes Weiß, Tobias Meischl, Fabian Kütting, Dirk-Thomas Waldschmidt, Pompilia Radu, Michael Schultheiß, Kai-Henrik Peiffer, Thomas J. Ettrich, Arndt Weinmann, Henning Wege, Marino Venerito, Jean-Francois Dufour, Christian M. Lange, Matthias Pinter, Oliver Waidmann
Publikováno v:
Liver Cancer, Pp 1-10 (2021)
Background and Aims: The multikinase inhibitor cabozantinib has been approved for hepatocellular carcinoma (HCC) previously treated with sorafenib. We report safety and efficacy data of an international, multicenter, real-life cohort of patients with
Externí odkaz:
https://doaj.org/article/49aa2979d981472fba28858c369ad697
Autor:
Sabrina Welland, Catherine Leyh, Fabian Finkelmeier, André Jefremow, Kateryna Shmanko, Maria A. Gonzalez-Carmona, Arne Kandulski, Petia Jeliazkova, Jan Best, Thorben W. Fründt, Angela Djanani, Maria Pangerl, Andreas Maieron, Richard Greil, Christina Fricke, Disorn Sookthai, Rainer Günther, Andreas Schmiderer, Henning Wege, Marino Venerito, Ursula Ehmer, Martina Müller, Christian P. Strassburg, Arndt Weinmann, Jürgen Siebler, Oliver Waidmann, Christian M. Lange, Anna Saborowski, Arndt Vogel
Publikováno v:
Liver Cancer, p 1 (2022)
Background Lenvatinib is approved as first-line treatment for patients with advanced hepatocellular carcinoma (HCC). The efficacy of lenvatinib in Caucasian real-world patients is insufficiently defined. The purpose of this study was to evaluate the
Externí odkaz:
https://doaj.org/article/8a92700df3fd4606aa03d07ae73baa60
Autor:
Catherine Leyh, Niklas Heucke, Clemens Schotten, Matthias Büchter, Lars P. Bechmann, Marc Wichert, Alexander Dechêne, Ken Herrmann, Dominik Heider, Svenja Sydor, Peter Lemmer, Johannes M. Ludwig, Josef Pospiech, Jens Theysohn, Robert Damm, Christine March, Maciej Powerski, Maciej Pech, Mustafa Özcürümez, Jochen Weigt, Verena Keitel, Christian M. Lange, Hartmut Schmidt, Ali Canbay, Jan Best, Guido Gerken, Paul P. Manka
Publikováno v:
Cancers; Volume 14; Issue 19; Pages: 4584
Background and Aims: Radioembolization (RE) has recently demonstrated a non-inferior survival outcome compared to systemic therapy for advanced hepatocellular carcinoma (HCC). Therefore, current guidelines recommend RE for patients with advanced HCC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82fa0316ef2dc8fc40e146622969f871
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85139853563
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85139853563
Autor:
Catherine Leyh, Niklas Heucke, Clemens Schotten, Matthias Buechter, Lars Bechmann, Marc Wichert, Alexander Dechene, Ken Hermann, Antonios Katsounas, Mustafa Özcürümez, Dominik Heider, Svenja Sydor, Johannes M. Ludwig, Jens Theysohn, Robert Damm, Maciej Powerski, Maciej Pech, Ali Canbay, Jochen Weigt, Verena Keitel-Anselmino, Christian Lange, Jan Best, Paul Manka
Poster-Abstract
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34688e2abbf459106ed01014d751a213
Autor:
Catherine Leyh, Ursula Ehmer, Daniel Roessler, Alexander B. Philipp, Florian P. Reiter, Petia Jeliazkova, Leonie S. Jochheim, Matthias Jeschke, Janina Hammig, Johannes M. Ludwig, Jens M. Theysohn, Andreas Geier, Christian M. Lange
Publikováno v:
Cancers; Volume 14; Issue 8; Pages: 1975
The optimal treatment sequence of tyrosine kinase inhibitor (TKI)-based therapy in patients with hepatocellular carcinoma (HCC) remains unclear. Therefore, sequential systemic therapy after first-line therapy with sorafenib or lenvatinib was compared
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5a97175dbe22d4985b687a612e973b2
https://www.ncbi.nlm.nih.gov/pubmed/35454881
https://www.ncbi.nlm.nih.gov/pubmed/35454881
Autor:
Marcel Binnebösel, Frank Tacke, Christian Trautwein, Catherine Leyh, Ulf P. Neumann, Thomas Longerich, Patrick H. Alizai, Mihael Vucur, Tom Florian Ulmer, Tom Luedde, Wenzel Schoening, Florian Heitkamp, Christoph Roderburg, Alexander Koch, Sven H. Loosen
Publikováno v:
OncoTarget, 9(43), 27027-27038. Impact Journals LLC
// Sven H. Loosen 1, * , Frank Tacke 1, * , Marcel Binnebosel 2 , Catherine Leyh 3 , Mihael Vucur 3 , Florian Heitkamp 3 , Wenzel Schoening 2 , Tom F. Ulmer 2 , Patrick H. Alizai 2 , Christian Trautwein 1 , Alexander Koch 1 , Thomas Longerich 4, 5 ,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72954d21969ba94fcfbd00e9c5707090
https://doi.org/10.18632/oncotarget.25471
https://doi.org/10.18632/oncotarget.25471
Autor:
Christian M. Lange, Manuel Weber, Lale Umutlu, Heiner Wedemeyer, Pedro Fragoso Costa, Michael Nader, Benedikt M. Schaarschmidt, Francesco Barbato, Ken Herrmann, Justin Ferdinandus, Catherine Leyh, Miriam Sraieb, Nader Hirmas, Wolfgang P. Fendler, Christoph Rischpler
Publikováno v:
J Nucl Med
Hepatocellular carcinoma (HCC) is the sixth most prevalent cancer and the third most frequent cause of cancer-related death. A growing number of local and systemic therapies are available, and accurate staging is critical for management decisions. We
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23517f99b574ef8ee5e680a124dbfa82
https://europepmc.org/articles/PMC8882890/
https://europepmc.org/articles/PMC8882890/
Autor:
Christiane K. Kuhl, Fabian Benz, Christian Trautwein, Catherine Leyh, Frank Tacke, Mihael Vucur, Sven H. Loosen, Philipp Bruners, Christoph Roderburg, Tom Luedde, Maximilian Schulze-Hagen
Publikováno v:
International Journal of Molecular Sciences
Volume 19
Issue 6
International journal of molecular sciences 19(6), 1766 (2018). doi:10.3390/ijms19061766
International Journal of Molecular Sciences, Vol 19, Iss 6, p 1766 (2018)
Volume 19
Issue 6
International journal of molecular sciences 19(6), 1766 (2018). doi:10.3390/ijms19061766
International Journal of Molecular Sciences, Vol 19, Iss 6, p 1766 (2018)
While surgical resection represents the standard potentially curative therapy for liver cancer, transarterial chemoembolization (TACE) has evolved as a standard therapy for intermediate-stage hepatocellular carcinoma (HCC) as well as liver metastases
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b743277f806be7f4ff51f4848a18b170